NewAmsterdam CAO sells shares after option exercise

NewAmsterdam Pharma Co N.V.’s Chief Accounting Officer Louise Frederika Kooij reported option exercises and share sales in late January 2026.

Rhea-AI Filing Summary

NewAmsterdam Pharma Co N.V.’s Chief Accounting Officer Louise Frederika Kooij reported option exercises and share sales in late January 2026. On January 27, 2026, she exercised 39,816 options at an exercise price of $10.90 per ordinary share and acquired the same number of ordinary shares.

That same day she sold 39,816 ordinary shares at a weighted average price of $32.62 per share, leaving 24,353 ordinary shares directly owned afterward. On January 28, 2026, she exercised another 32,612 options at $10.90 per share and acquired 32,612 ordinary shares, then sold 32,612 ordinary shares at a weighted average price of $31.80 per share.

After these transactions, she directly held 24,353 ordinary shares and 73,134 options (options with a $10.90 exercise price and an expiration date of January 1, 2033). The filing notes that the sale prices are weighted averages across multiple trades within the stated price ranges.

Insider Trade Summary

Exercise and Sale: 72,428 shares ($1.55M approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Kooij Louise Frederika

Role Chief Accounting Officer

Sold 72,428 shs ($2.34M)

Approx. gross sale proceeds $2.34M

Approx. exercise cost $789K

Approx. pre-tax spread $1.55M

Type	Security	Shares	Price	Value
Exercise	Option (right to buy)	32,612	$0.00	$0.00
Exercise	Ordinary Shares	32,612	$10.90	$355K
Sale	Ordinary Shares	32,612	$31.80	$1.04M
Exercise	Option (right to buy)	39,816	$0.00	$0.00
Exercise	Ordinary Shares	39,816	$10.90	$434K
Sale	Ordinary Shares	39,816	$32.62	$1.30M

Holdings After Transaction: Option (right to buy) — 73,134 contracts (Direct); Ordinary Shares — 24,353 shares (Direct)

Footnotes (3)

1. F1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.29 to $32.97 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.58 to $32.53 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
3. F3. The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.

FAQ

What insider transactions did NewAmsterdam Pharma (NAMS) report for Louise Kooij?

NewAmsterdam Pharma’s Chief Accounting Officer Louise Kooij exercised stock options and sold ordinary shares on January 27 and 28, 2026. She exercised 72,428 options at $10.90 per share and sold an equal number of shares at weighted average prices above $31 per share.

How many NewAmsterdam Pharma (NAMS) shares did the CAO sell and at what prices?

Louise Kooij sold 39,816 ordinary shares on January 27, 2026 at a weighted average price of $32.62, and 32,612 shares on January 28, 2026 at a weighted average price of $31.80. Each day’s price reflects multiple trades within disclosed price ranges.

How many NewAmsterdam Pharma (NAMS) options did the CAO exercise in January 2026?

On January 27, 2026, Louise Kooij exercised 39,816 options with a $10.90 exercise price. On January 28, 2026, she exercised an additional 32,612 options at the same $10.90 exercise price, converting them into ordinary shares before selling those shares.

What are Louise Kooij’s remaining holdings in NewAmsterdam Pharma (NAMS) after these trades?

Following the reported January 2026 transactions, Louise Kooij directly held 24,353 ordinary shares of NewAmsterdam Pharma and 73,134 stock options. These options have a $10.90 exercise price and an expiration date of January 1, 2033, subject to their vesting schedule.

What vesting terms apply to NewAmsterdam Pharma (NAMS) options held by the CAO?

The option grant was made on January 1, 2023. Twenty‑five percent of the underlying shares vest on the one‑year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments over three years, contingent on continued service.

How were the NewAmsterdam Pharma (NAMS) share sale prices calculated in this Form 4?

For both sale dates, the reported prices are weighted averages across multiple trades. On January 27, 2026, trades occurred between $32.29 and $32.97 per share. On January 28, 2026, trades ranged from $31.58 to $32.53 per share, producing the disclosed averages.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/29/2026 - 04:40 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kooij Louise Frederika

(Last) (First) (Middle)

C/O NEWAMSTERDAM PHARMA COMPANY N.V.

GOOIMEER 2-35

(Street)

NAARDEN P7 1411 DC

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NewAmsterdam Pharma Co N.V. [ NAMS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	01/27/2026		M		39,816	A	$10.9	64,169	D
Ordinary Shares	01/27/2026		S		39,816	D	$32.62(1)	24,353	D
Ordinary Shares	01/28/2026		M		32,612	A	$10.9	56,965	D
Ordinary Shares	01/28/2026		S		32,612	D	$31.8(2)	24,353	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	$10.9	01/27/2026		M			39,816	(3)	01/01/2033	Ordinary Shares	39,816	$0.00	105,746	D
Option (right to buy)	$10.9	01/28/2026		M			32,612	(3)	01/01/2033	Ordinary Shares	32,612	$0.00	73,134	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.29 to $32.97 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.58 to $32.53 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

3. The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.

	/s/ Louise Kooij	01/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.